Business
Caris Life Sciences Announces Preliminary Fourth Quarter and Full Year 2025 Results
Full year revenue growth of approximately 94% driven by strong performance in molecular profiling servicesIRVING, Texas, Jan. 12, 2026 /PRNewswire/ -- Caris
About this update from Caris Life Sciences, Inc.
[{"type":"text","content":"Full year revenue growth of approximately 94% driven by strong performance in molecular profiling servicesIRVING, Texas, Jan. 12, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025.\n \n \n \n \n \n \n \nFourth quarter 2025 preliminary unaudited financial resultsFor the three-month period ended December 31, 2025, as compared to the same period of 2024:Total revenue of approximately $281 million, an increase of approximately 116%.Consisting of approximately $270 million of Molecular Profiling services revenue (including approximately $81 million of prior period true-ups) and approximately $11 million of Pharma research and developmental services revenue.Completed approximately 52,700 clinical therapy selection cases, an increase of approximately 20% and consisting of approximately 44,150 MI Profile cases and approximately 8,550 Caris Assure cases.Full year 2025 preliminary unaudited financial resultsFor the twelve-month period ended December 31, 2025, as compared to the same period of 2024:Total revenue of approximately $800 million, an increase of approximately 94%.Consisting of approximately $755 million of Molecular Profiling services revenue (including approximately $33 million of prior year true-ups) and approximately $45 million of Pharma research and developmental services revenue.Completed approximately 199,300 clinical therapy selection cases, an increase of 22% and consisting of approximately 170,300 MI Profile cases and approximately 29,000 Caris Assure cases.Preliminary unaudited cash, cash equivalents, restricted cash and marketable securities were approximately $802 million as of December 31, 2025, a net increase of approximately $43 million from September 30, 2025.\"2025 was a breakthrough year for Caris as we became a public company and demonstrated the scale and impact of our comprehensive molecular profiling platform,\" said David D. Halbert, Founder, Chairman and CEO of Caris Life Sciences. \"We continue to be focused on expanding clinical adoption, advancing a differentiated pipeline, and building the foundation for what we believe will be a new standard in precision medicine.\"This announcement...